Follow-On Brand Drugs Could Draw FTC Anticompetitive Scrutiny
This article was originally published in The Tan Sheet
Executive Summary
The introduction of certain follow-on brand drugs as the original product nears patent expiration could raise anticompetitive concerns at the Federal Trade Commission, according to FTC Commissioner Pamela Harbour
You may also be interested in...
Prilosec OTC, Nexium Launches Fed “Shark Fin” Monopoly Plan, Suit Claims
Elements of the Prilosec OTC launch, ranging from the drug's 14-day term of use to supply shortages during its time on the market, were part of a plan by AstraZeneca to interfere with generic competition for its prescription proton pump inhibitors, retailers allege in a lawsuit against the U.K. drug maker
Prilosec OTC, Nexium Launches Fed “Shark Fin” Monopoly Plan, Suit Claims
Elements of the Prilosec OTC launch, ranging from the drug's 14-day term of use to supply shortages during its time on the market, were part of a plan by AstraZeneca to interfere with generic competition for its prescription proton pump inhibitors, retailers allege in a lawsuit against the U.K. drug maker
Prilosec OTC, Nexium Launches Fed “Shark Fin” Monopoly Plan, Suit Claims
Elements of the Prilosec OTC launch, ranging from the drug's 14-day term of use to supply shortages during its time on the market, were part of a plan by AstraZeneca to interfere with generic competition for its prescription proton pump inhibitors, retailers allege in a lawsuit against the U.K. drug maker